The benefits of exogenous synthetic or animal-derived surfactants for prevention or treatment of respiratory distress syndrome (RDS) are well established. Data from head-to-head trials comparing animal-derived surfactants primarily with the synthetic surfactant colfosceril suggest that the major clinical advantages afforded by the presence of surfactant protein (SP)-B and SP-C in animal-derived preparations relate to faster onset of action, a reduction in the incidence of RDS when used prophylactically, and a lower incidence of air leaks and RDS-related deaths. However, no benefits in terms of overall mortality or BPD have been shown in these head-to-head comparisons. Findings from trials of a new-generation synthetic surfactant containing a peptide that mimics SP-B, as well as their follow-up study suggest that its administration improves short-term clinical outcomes compared with colfosceril and results in survival through 1 year of age, which is at least comparable, if not perhaps superior, to that seen with animal-derived surfactants.
Introduction
Animal-derived surfactants from bovine or porcine sources currently in clinical use contain various phospholipids and variable quantities of surfactant proteins (SP)-B and -C, whereas currently available synthetic surfactants contain only phospholipids and no surfactant proteins. 1 Although synthetic surfactants have potential safety advantages over animal-derived products, they seem to be clinically inferior to animal-derived surfactants. This assertion is based primarily on the results of a meta-analysis of 11 controlled trials comparing these two classes of surfactants, which showed a marginally significant lower mortality and a lower risk of pneumothorax plus more rapid weaning with animal-derived surfactants compared with synthetic surfactants. 2 However, no reductions in the incidence of bronchopulmonary dysplasia (BPD) were shown in that meta-analysis or in any individual trials comparing these surfactants. None of these surfactant comparison trials reported outcomes beyond the initial stay in the neonatal intensive care unit (NICU) .
Multiple studies have shown that synthetic surfactants lacking SP-B and SP-C fail to lower surface tension in vitro, whereas animal-derived surfactants can reduce it to an extent somewhat directly related to their SP content. 3, 4 The absence of SP-B seems to be particularly important as animals or humans lacking SP-B because of a genetic mutation develop a fatal form of respiratory failure during the neonatal period. 5, 6 In contrast, individuals with mutations in SP-C develop interstitial lung disease as adults rather than respiratory disease during the neonatal period. 7 The purpose of this review is to summarize the results from published randomized trials comparing animal-derived with synthetic surfactants devoid of proteins and to review the evidence from clinical trials of a new-generation synthetic surfactant that contains phospholipids and a peptide that mimics SP-B. 8 For a summary of all published head-to-head comparison trials of surfactants, including comparisons between animal-derived surfactants, the reader is referred to the recent review by Moya and Maturana. 9 Composition of commonly used surfactants The main characteristics and components of the most studied and used synthetic and animal-derived surfactants are found in Table 1 . The amount of phospholipids administered per dose of surfactant is quite variable and ranges from 50 to 200 mg kg -1 . The volume of each dose and interval for administration recommended by the various manufacturers are also different. Colfosceril and pumactant contain no SPs. Animal-derived surfactants differ in their contents of SP-B and SP-C.
3 Calfactant (Infasurf, Forest Laboratories, Inc., St Louis, MO, USA) contains the highest concentration of SP-B on a weight basis, followed by poractant (Curosurf, Chiesi Farmaceutici, Parma, Italy). Beractant (Survanta, Ross Products Division, Abbott Laboratories, Columbus, OH, USA) has the lowest content of SP-B of these animal-derived surfactants. The content of the SP-B mimic in lucinactant (Surfaxin, Discovery Laboratories, Warrington, PA, USA) is discussed later.
Controlled trials comparing non-protein-containing synthetic with animal-derived surfactants Since the advent of exogenous surfactant therapy, several animal-derived but only two synthetic surfactants devoid of SPs have been used clinically, namely colfosceril (Exosurf, GlaxoSmithKline, Brentford, UK) and pumactant (artificial lung expanding compound, Britannia Pharmaceuticals Ltd, Redhill, Surrey, England). Over the past decade and a half, there have been many randomized trials comparing these two major classes of surfactants, although most have used a treatment rather than a prophylactic approach. Soll and Blanco 2 conducted a widely quoted systematic review of 11 trials comparing animal-derived surfactants with synthetic surfactants. Seven of ten of the trials included in that review compared colfosceril with beractant, two trials compared it with calfactant and one trial with poractant alfa. Only one trial compared the only other synthetic surfactant used clinically, pumactant, with poractant. These authors concluded that both types of surfactants are effective in the treatment and prevention of respiratory distress syndrome (RDS). However, they also concluded that, when taken together, use of animal-derived surfactants resulted in fewer deaths, greater early improvement in the requirement for ventilatory support and a lower overall incidence of pneumothorax than synthetic products containing only phospholipids. No advantages in terms of reduction in the incidence of BPD were described in this systematic review or in any of the individual trials included in it. In addition, a small but significant increase in the incidence of intraventricular hemorrhage (IVH) among infants treated with animal-derived surfactants was reported.
Colfosceril versus beractant
Five of the six published studies comparing colfosceril with beractant were for treatment of RDS with the exception of the recent lucinactant prophylaxis trial comparing this surfactant with colfosceril, in which infants were also randomized to beractant in a 2:2:1 scheme. [10] [11] [12] [13] [14] [15] A major advantage of these studies lies in the fact that several thousand infants have been included. A major limitation in the design of these studies is that none of them were masked, except for the comparison included within the lucinactant trial. Moreover, the use of antenatal steroids in all but the lucinactant trials was <40%, reflecting the time when they were conducted. The cumulative results show that overall mortality was 18.4% for beractant and 20.9% for colfosceril (relative risk (RR) 0.89, 95% CI 0.75 to 1.05). Only the incidence of pneumothorax was reduced using beractant versus colfosceril when used for treatment of RDS (RR 0.61, 95% CI 0.47 to 0.78) with a number needed to treat (NNT) of 21, but not for prophylaxis of RDS. No changes in need for supplemental oxygen at 36 weeks were noted (23.5 versus 25.6%, respectively). Nonetheless, those trials for treatment of RDS in which ventilatory settings were reported showed more rapid reductions of supplemental oxygen and ventilatory pressures among infants given beractant, which averaged about 7% lower FiO 2 and 0.7 cm H 2 O lower mean airway pressure over the first 48 h. It should be noted that, when colfosceril was compared with beractant using a prophylactic approach, a secondary comparison in one of the lucinactant trials, beractant reduced the incidence of RDS at 24 h (33.3 versus 47.2%, respectively), but did not result in less overall deaths, deaths due to RDS or other complications. 15 Collectively, these data show that beractant has clinical advantages such as less pneumothorax and more rapid weaning over colfosceril mainly when used for treatment of RDS, although it is also more effective in prevention of RDS than colfosceril. No benefits in terms of overall mortality or BPD have been shown.
Colfosceril versus calfactant
There have been only two trials comparing colfosceril and calfactant, one for prophylaxis and one for treatment of RDS. 16, 17 These were large, multicenter trials that recruited almost two thousand infants, and had a more sophisticated design than the Abbreviations: DPPC, dipalmitoylphosphatidylcholine; PG, phosphatidylglycerol; POPG, palmitoyloleylphosphatidylglycerol; SP-B, surfactant protein B; SP-C, surfactant protein C.
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comparisons of beractant and poractant versus colfosceril, including blinding and partial adjudication of primary outcomes. Antenatal steroids exposure was either not reported or occurred in less than one-third of the infants. Crossover use of surfactants was permitted, but there were no ventilatory guidelines. In the trial for prophylaxis of RDS use of calfactant resulted in a lower incidence of RDS at 24 h (16 versus 42%, respectively, P<0.001) and in RDS-related deaths (1.7 versus 5.4%, respectively, P ¼ 0.001). Also, infants given calfactant required less supplemental oxygen and mean airway pressure during the first 72 h after delivery. However, there were no significant differences in overall mortality analyzed per protocol (15.1% in the calfactant group versus 17.5% in the colfosceril group), use of oxygen at 36 weeks (11.8 versus 9.7%, respectively) or pneumothorax (3.8 versus 6.1%, respectively), although the air leaks at 7 days were less frequent among infants given calfactant. A concerning finding of this trial was the higher incidence of severe IVH and PVL in the calfactant group (17.6 versus 11.4%, respectively; RR 1.54, 95% CI 1.11 to 2.14), although this may have been influenced by the lesser number of deaths due to RDS among these infants. When used for treatment of RDS, the use of calfactant resulted in faster weaning of approximately the same magnitude as that seen in the comparisons of beractant and colfosceril and less pneumothoraces than when colfosceril was given (5.5 versus 10.3%, respectively; RR 0.54, 95% CI 0.35 to 0.84) with a NNT of 21, but no significant reductions in overall mortality at discharge (9.9 versus 12.0%, respectively) or oxygen use near term (5 versus 4%, respectively) were reported. Although no significant differences in total or severe IVH were identified, the incidence of PVL was again higher in the group treated with calfactant (3.3 versus 1.3%, respectively, P ¼ 0.015). Both of these studies reported peridosing effects, which were significantly more common among infants given calfactant particularly during repeat dosing. This cumulative experience comparing calfactant, the animal-derived surfactant with the highest concentration of SP-B, with colfosceril suggests that most of the clinical benefits favoring calfactant relate to acute measures such as more rapid weaning and less air leaks, as well as being more effective in preventing RDS, rather than having a significant impact on overall mortality or BPD. It remains somewhat a concern that both of these well-designed, masked studies, which included large numbers of infants, showed increases in either severe IVH or PVL associated with the use of calfactant. This question will probably remain unresolved since no follow-up data from these trials have ever been reported.
Colfosceril or pumactant versus poractant
There have been only two trials comparing colfosceril with poractant although one of them did not report respiratory outcomes. Thus, the only one contributing data is that of Kukkonen et al., 18 which compared these surfactants for treatment of RDS. The trial was conducted in three NICUs and the dose of poractant used was 100 mg kg -1 . The primary outcomes were the duration of mechanical ventilation and supplemental oxygen. It enrolled 230 infants, making it the third largest comparison trial of poractant. Antenatal steroid use was better than in earlier trials at about 60%, but the study was not masked and there was also crossover use of surfactants. Consistent with other trials comparing animal-derived and synthetic surfactants without proteins, the group treated with poractant had lower oxygen requirements and mean airway pressure during the first few hours after treatment. However, there were no significant differences in overall mortality (20.4% in the poractant group versus 13% in the colfosceril group; RR 1.56, 95% CI 0.86 to 2.83), pneumothorax (9.7 and 9.6%, respectively) or oxygen use at 36 weeks (33.6 versus 27%, respectively). Unexpectedly, the incidence of sepsis was significantly higher in the group treated with poractant (11 versus 4%, RR 3.17, 95% CI 1.05 to 9.52), a finding that has not been replicated in other studies.
Similar doses of 100 mg kg -1 of pumactant and poractant were compared in a multicenter, unmasked trial in 12 NICUs in the United Kingdom, which enrolled infants between 25 to 29 weeks of gestation intubated for presumed RDS. 19 The primary outcome for this trial was duration of high dependency care (respiratory support and oxygen use). About two-thirds of all infants received their assigned surfactant by 30 min after delivery. The trial was stopped after approximately 90% of the estimated sample size had been enrolled because of a large difference in mortality among groups, but data were reported only for about 200 infants. No difference in primary outcome was seen; however, a significant decrease in overall mortality among infants receiving poractant was reported (14.1% in the poractant group versus 31% in the pumactant group; RR 0.46, 95% CI 0.26 to 0.80). Also, the occurrence of pneumothorax was decreased (11.1 versus 22%, respectively; RR 0.51, 95% CI 0.26 to 0.99), but no difference in use of oxygen at 36 weeks was shown (46.5 versus 42%, respectively). This is the only study to ever show a significant difference in overall mortality between an animal-derived and a synthetic surfactant. Without these results, the difference in mortality between synthetic and animal-derived surfactants reported by Soll and Blanco in their meta-analysis is no longer significant. 2 Collectively, these data, albeit based on a relatively small number of infants, show that poractant, when used at a dose of 100 mg kg -1 , has important clinical advantages only over pumactant in overall mortality and pneumothorax, but not over colfosceril.
New-generation protein-containing synthetic surfactant
Lucinactant is a new-generation synthetic surfactant that contains two phospholipids and a high concentration of the synthetic 21-amino-acid hydrophobic peptide sinapultide (KL 4 peptide). This peptide resembles the hydrophobic-hydrophilic amino-acid pattern of the tail end of SP-B. 8 The concentration of sinapultide in lucinactant is higher than the concentration of SP-B in current animal-derived products. This surfactant has greater resistance to oxidation and peroxidation than beractant and was shown to improve pulmonary function in an animal model of RDS and a pilot study involving preterm infants with established RDS. [20] [21] [22] Lucinactant comes in a solution containing 30 mg of phospholipids per ml for a total recommended dose of 5.8 ml kg -1 or 175 mg of phospholipids. It requires warming to 44 1C followed by vigorous shaking and cooling to body temperature before administration. 15 To date there have been two multicenter, phase III, double-blind, randomized, controlled trials examining the efficacy of lucinactant in the prevention of RDS. 15, 23 Inclusion criteria, approach to surfactant administration and time periods when the studies were conducted were fairly similar for both trials ( Table 2 ). The SELECT (Safety and Effectiveness of Lucinactant versus Exosurf in a Clinical Trial) study compared lucinactant with colfosceril. It was designed as a superiority trial that tested the hypothesis of whether the addition of sinapultide to a phospholipid mixture conferred any clinical benefit compared with a surfactant providing only phospholipids. Beractant was used in the trial as a reference arm. The only published data comparing colfosceril with beractant for prevention of RDS come from this trial. A total of 50 NICUs enrolled 1294 preterm infants between 24 and 32 weeks of gestational age and between 600 and 1250 g birth weight. These were randomized to lucinactant, colfosceril and beractant in a 2:2:1 scheme. The primary outcomes of this study were the incidence of RDS at 24 h and RDS-related mortality through 14 days of age; these outcomes are essentially similar to those used in the comparison of calfactant with colfosceril. 16 These outcomes were adjudicated by an independent, masked committee of neonatologists and pediatric radiologists. Administration of the assigned surfactants was masked and no crossover use of surfactants was permitted. Moreover, the trial included ventilatory and extubation guidelines. All infants received the initial dose of surfactant before 30 min after birth. Antenatal steroid use was approximately 80%. Administration of lucinactant significantly reduced the incidence of RDS compared with colfosceril (OR 0.68, 95% CI 0.52 to 0.89), and RDS-related mortality through 14 days of age was also significantly reduced compared with both colfosceril (OR 0.43, 95% CI 0.25 to 0.73) and beractant (OR 0.35, 95% CI 0.18 to 0.66). The incidence of BPD at 36 weeks postmenstrual age (PMA) was lower among those infants receiving lucinactant compared with those who got colfosceril (OR 0.75, 95% CI 0.56 to 0.99), but not beractant. Proportionally, more infants were alive at 36 weeks PMA compared with beractant (OR 0.67, 95% CI 0.45 to 1.00, P ¼ 0.05). No difference in pneumothorax or other complications of prematurity were reported. Given that this was the first large trial of lucinactant, side effects such as reflux, dose interruption during administration and endotracheal tube obstruction were carefully evaluated. These were shown either to occur similarly among groups or to be slightly more common among infants receiving lucinactant or beractant than colfosceril. The incidence of these peridosing effects was well within values reported earlier among the few other surfactant comparison trials that have evaluated them. 10, 16, 17 The STAR (Surfaxin in Therapy Against RDS) trial compared lucinactant with poractant. 23 In this masked study, which was designed as a non-inferiority trial based on data from the only earlier placebo-controlled trial of poractant, the clinical question asked was whether surfactant preparations, one synthetic and one animal-derived, when given in similar concentrations of phospholipids but different amounts of SP-B or its mimic, would result in a clinically meaningful difference in the primary outcome of being alive without BPD at 28 days. Twenty-two NICUs enrolled 124 preterm infants between 600 to 1250 g, which were randomized to receive lucinactant and 128 that received poractant, but data on only 243 infants who received either surfactant within the predetermined window of 30 min after delivery were reported. The upper limit for gestational age in the STAR trial was limited to infants younger than 29 weeks. Antenatal steroids were given to 85 to 88% of infants enrolled. The study was stopped early after only about 50% of the estimated sample size had been enrolled, primarily because of very slow recruitment. Nonetheless, this is the One-year outcomes of the lucinactant trials A planned follow-up of participating infants out to 1-year corrected age from both trials has been reported recently. 24 Given the similarity of these trials in the populations studied, treatment approach, end points and contemporary nature, a secondary goal defined a priori of this follow-up study was to compare the outcome of infants receiving lucinactant with the outcome of those who received other classes of surfactants after combining data from both trials. In the subsequent follow-up of infants in the SELECT trial, an exceedingly small proportion of infants were lost (<2%), whereas none of the infants in the STAR trial were lost to follow-up. Prespecified rules for the primary analysis in both trials stated that infants for whom consent after randomization was withdrawn or who were lost to follow-up were counted as deaths. Nonetheless, survival comparisons on raw data from infants for whom data were available without imputation for death were also reported. All detailed data are easily accessible in the original publication and are not within the scope of this review.
Using Kaplan-Meier survival analysis in the SELECT study, no significant differences were found in the proportion of infants that were alive through 1-year corrected age comparing those given lucinactant, colfosceril or beractant. In the STAR trial, significantly more infants treated with lucinactant were alive through 1-year corrected age compared with those receiving poractant (P ¼ 0.04). In the combined analysis, survival through 1-year corrected age of those infants receiving lucinactant was slightly higher compared with the survival of those who received animal-derived surfactants (P ¼ 0.05). There were no significant differences between groups in either study with regard to duration of mechanical ventilation, supplemental oxygen and initial hospitalization. Postdischarge re-hospitalization was frequent and its incidence did not differ between surfactant groups in the SELECT trial. Likewise, there were no significant differences among survivors from the different groups in their neurological evaluations at 1-year corrected age.
Conclusions
Multiple clinical trials and extensive clinical experience have shown that animal-derived surfactants that contain variable amounts of SP-B and SP-C and synthetic surfactants devoid of SPs decrease respiratory morbidity and mortality in preterm infants with surfactant deficiency. Head-to-head trials have compared animal-derived surfactants primarily with the synthetic surfactant colfosceril. Only some of these head-to-head comparison trials have shown differences in important clinical outcomes. Data from these studies suggest that the major clinical advantages afforded by the presence of SP-B and SP-C in animal-derived preparations relate to faster onset of action, a reduction in the incidence of RDS when used prophylactically, and a lower incidence of air leaks and RDS-related deaths. However, no major benefits in terms of overall mortality or BPD have been shown in these head-to-head comparisons.
Recently, a new-generation synthetic surfactant containing a peptide that mimics SP-B has been evaluated in two clinical trials. Findings from these trials 15, 23 as well as their follow-up study 24 suggest that administration of lucinactant improves short-term clinical outcomes compared with colfosceril and results in a survival through 1 year of age that is at least comparable, if not perhaps superior, to that seen with the animal-derived surfactants beractant and poractant. This new surfactant and the trials examining its clinical use have not been without criticism. 25, 26 However, in a recent statement the American Academy of Pediatrics concluded that 'new synthetic surfactants with surfactant protein like activity are promising new treatments for surfactant-deficiency disorders'. 27 Future studies using newer approaches to surfactant therapy may be able to further improve the outcome for preterm infants at risk for or with established RDS. Disclosure F Moya is a paid consultant for Discovery Laboratories but holds no equity. This paper was based on a talk presented at the Evidence vs Experience in Neonatal Practices Fifth Annual CME Conference that was supported by an unrestricted educational grant from Dey, LP.
